GNLX:NASDAQ
Genelux Corp
$ 2.48
arrow_downward
-0.80%(-0.020) 1D
10-р сарын 9, 11:57:04 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$ 2.48
High
$ 2.55
Low
$ 2.47
Mkt. cap
112.21 сая
Avg. vol.
275.44 мян
Volume
30.54 мян
52-wk high
$ 8.54
52-wk low
$ 2.29
EPS
-$ 0.87
Beta
0.59
Shares outstanding
45.24 сая
No. of employees
26
Open
$ 2.48
High
$ 2.55
Low
$ 2.47
Mkt. cap
112.21 сая
Avg. vol.
275.44 мян
Volume
30.54 мян
52-wk high
$ 8.54
52-wk low
$ 2.29
EPS
-$ 0.87
Beta
0.59
Shares outstanding
45.24 сая
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 долоо хоногийн өмнө
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Force Index
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitegenelux.com